Related Experiment Videos
MC 1288--a vitamin D analogue with immunosuppressive effects on heart and small bowel grafts
1Department of Transplantation Surgery, University Hospital, Uppsala, Sweden.
Abstract:
The vitamin D analogue MC 1288 (20-epi-1 alpha,25-dihydroxycholecalciferol) was tested here for its possible immunosuppressive properties in vivo using different rat transplantation models. MC 1288, in a dose of 0.1 microgram/kg daily, administered intraperitoneally for 10 days, was found to be effective in prolonging cardiac allograft survival. Untreated recipients rejected their grafts around day 8 while MC 1288 treatment delayed rejection until day 22 (P < 0.001). Addition of the immunostimulatory drug LS-2616 (Linomide) reduced the immunosuppressive effect of MC 1288 and rejection occurred around day 11. The immunosuppressive effect of MC 1288 on rejection following small bowel transplantation was determined by measuring the amounts of hyaluronan (HA) secreted into the intestinal lumen. On day 6 post-transplantation the amounts of intraluminal HA in untreated animals was 29.2 +/- 5.3 ng/min and cm, while in MC 1288-treated animals it was just 5.0 +/- 1.6 ng/min and cm (P < 0.01). We conclude that MC 1288 has immunosuppressive effects that may make it suitable for the prevention of graft rejection.
Insights
The vitamin D analogue MC 1288 demonstrated significant immunosuppressive properties in rat models. This compound effectively prolonged cardiac allograft survival and reduced markers of rejection in small bowel transplants.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Science
Background:
- Graft rejection remains a major challenge in organ transplantation.
- Novel immunosuppressive agents are needed to improve transplant outcomes.
Purpose of the Study:
- To evaluate the in vivo immunosuppressive properties of the vitamin D analogue MC 1288.
- To assess MC 1288's efficacy in preventing graft rejection in rat transplantation models.
Main Methods:
- MC 1288 was administered to rats undergoing cardiac and small bowel transplantation.
- Cardiac allograft survival was monitored.
- Hyaluronan secretion was measured in small bowel transplant recipients.
Main Results:
- MC 1288 significantly prolonged cardiac allograft survival from 8 to 22 days (P < 0.001).
- Co-administration with LS-2616 diminished MC 1288's immunosuppressive effect.
- MC 1288 reduced intraluminal hyaluronan levels in small bowel transplants (P < 0.01).
Conclusions:
- MC 1288 exhibits potent immunosuppressive effects in vivo.
- MC 1288 shows potential as a therapeutic agent for preventing organ graft rejection.